louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03669978: Endovascular Procedures With Computer Assistance in the Chronic Occlusive Arthritis of the Lower Limbs on the Femoro-popliteal Stage.
Official title: Endovascular Procedures With Computer Assistance in the Chronic Occlusive Arthritis of the Lower Limbs on the Femoro-popliteal Stage.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Peripheral Arterial Disease
Keywords: Occlusive arthritis
bone panorama
arterial panorama
Lead sponsor: Rennes University Hospital
Sponsor class: OTHER
First posted: 2018-09-13
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with chronic occlusive arthritis of the Lower Limbs with lesions on the femoro-popliteal stage and candidates for endovascular treatment of these lesions.

Brief summary: Pilot study to assess the feasibility of creation of a bone and arterial panorama by 2D-2D registration technique during endovascular femoro-popliteal procedures with a mobile C-arm X-ray system using EndoNaut® software.

Detailed description: The aim of this study is to show that it is possible to give a complete image of the area to be operated by the surgeon by creating a complete bone and arterial panorama of the femoro-popliteal axis with 2D-2D registration techniques. This study should have a clinical impact for the patient and caregiver. With this technique, we expect a reduction in the irradiation of the patient and the caregivers, a decrease in the volume of injected contrast product and a decrease in operating time.

Eligibility criteria: Inclusion Criteria:

* Patients with peripheral arterial disease of the lower limbs, all clinical stages, lesions of the femoro-popliteal stage and candidates for endovascular treatment of these lesions.
* Major patients
* Patients not opposed to their participation in the study

Exclusion Criteria:

* Patients requiring conventional surgical revascularization.
* Patient under legal protection (guardianship, safeguard of justice).
* Pregnant or lactating women

Primary outcomes:
measure: Quantification of the registration errors
timeFrame: At the inclusion day
measure: Volume of contrast product used during the routine care procedure (ml)
timeFrame: At the inclusion day
measure: Irradiation parameters: evaluation of the Fluoroscopy duration (min)
timeFrame: At the inclusion day
measure: Irradiation parameters: dose-area quantification (mGy/m2)
timeFrame: At inclusion
measure: Irradiation parameters: measurement of air Kerma (mGy)
timeFrame: At the inclusion day
measure: Irradiation parameters: evaluation of the number of required angiograms
timeFrame: At the inclusion day
measure: Operating time (min)
timeFrame: At the inclusion day
Secondary outcomes:
Other outcomes:
Locations:
city: Rennes
country: France
facility: Rennes Univesity Hospital
Study officials:
affiliation: Rennes University Hospital
name: Adrien Kaladji, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01419678: Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients
Official title: Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lung Transplant Infection
Fungal Infection
Keywords: posaconazole
PK blood sampling
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2011-08-18
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a single center, observational study of posaconazole PK sampling in lung transplant recipients. The patients enrolled will have up to 6 (3ml) pk samples (a total of 18 ml) and one 10ml blood sample for a total collection of 28ml of blood obtained over the entire study. In addition, the investigators will collect medical record information and any excess BAL samples available during the study (tests done as part of the patient's clinical care and the samples would have been discarded once diagnosis was made).

Detailed description: PK blood samples will be obtained around a clinical dosing of posaconazole

Eligibility criteria: Inclusion Criteria:

* 18 years of age and older receiving posaconazole post transplant as part of their care received a lung transplant

Exclusion Criteria:

* must meet inclusion criteria

Primary outcomes:
measure: measure the levels of posaconazole post dosing
timeFrame: 24 hours after dosing
Secondary outcomes:
measure: determine the posaconazole concentration within the pulmonary epithelial lining fluid (ELF) and alveolar cells
timeFrame: 1 year
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: UPMC
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Ryan Shields, Pharm D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02791178: Optical Coherence Tomography in STEMI
Official title: Plaque Evaluation by Optical Coherence Tomography and Its Association With Microvascular Obstruction in Reperfused STEMI Patients - The POMS Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: STEMI
Lead sponsor: National Heart Centre Singapore
Sponsor class: OTHER
First posted: 2016-06-06
Enrollment: 35
Sex: ALL
Minimum age (years): 21
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The patients presenting with a STEMI and undergoing PPCI will be screened and approached to participate in this study.

Brief summary: The overall objective of this research proposal is to use OCT to investigate those morphological culprit plaque characteristics associated with the risk of developing MVO in reperfused STEMI patients.

Detailed description: The specific research objectives include:

1. To use OCT to determine the type of plaque (plaque rupture, plaque erosion or calcified nodule) most associated with the presence and severity of MVO (as measured by IMR and cardiac MRI).
2. To use OCT to investigate the relationship between the extent of tissue protrusion and the amount of residual stent thrombus with the presence and severity of MVO (as measured by IMR and cardiac MRI).

Eligibility criteria: Inclusion Criteria:

1. Confirmed STEMI as per the in-charge consultant based on presenting history, ECG and angiogram findings.
2. \< 12 hours of onset of chest pain.
3. Ability to provide informed consent

Exclusion Criteria:

1. Previous myocardial infarction or coronary artery bypass graft surgery
2. Cardiac arrest or cardiogenic shock
3. Inability to advance the OCT catheter or to obtain good image quality
4. Ostial lesions
5. Significant renal impairment
6. Contraindications for cardiac MRI
7. Contraindication for adenosine (for IMR measurement)

Primary outcomes:
measure: All cause mortality
timeFrame: Two years
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: National Heart Centre Singapore
Study officials:
affiliation: National Heart Centre Singapore
name: Derek Hausenloy
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02434978: Doppler-guided Endoscopic Treatment in Peptic Ulcer Bleeding
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Peptic Ulcer Bleeding
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
First posted: 2015-05-06
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The present study is a randomized controlled trial (RCT) that examines if the outcome of peptic ulcer bleeding could be improved by use of doppler-guided endoscopic treatment.

Detailed description: This study evaluates if performance of a control endoscopy with doppler-guided endoscopic treatment is associated with an improved outcome in term of lower rate of rebleeding and lower rate of bleeding-related mortality. A potential risk of increased risk of complications (in particular perforation) among patients treated with control endoscopy is also evaluated. Outcomes are prospectively registered based on patient records.

Eligibility criteria: Inclusion Criteria:

* Peptic ulcer bleeding from ulcers classified as Forrest I-IIb

Exclusion Criteria:

* Severe comorbidity with a remaining life expectancy below 30 days

Primary outcomes:
measure: Rebleeding
timeFrame: 1 week
Secondary outcomes:
measure: Bleeding-related mortality
timeFrame: 1 month
measure: Complications to endoscopic therapy
timeFrame: 1 month
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Department of gastrointestinal surgery, Aalborg University Hospital
city: Odense
country: Denmark
facility: Department of gastroenterology, Odense University Hospital
Study officials:
References:
Clinical trial NCT05396378: Early Recovery After Cesarean Delivery - Maternal Glucose Homeostasis Following Preoperative Glucose Dose
Official title: Early Recovery After Cesarean Delivery - Maternal Glucose Homeostasis Following Preoperative Glucose Dose in Diabetic Parturients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gestational Diabetes
Cesarean Section Complications
Lead sponsor: Women's Hospital HUS
Sponsor class: OTHER
First posted: 2022-05-31
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Diabetic parturients excluding type I diabetics who visit the Helsinki University Central Hospital/Women's hospital for the treatment of their diabetes during pregnancy and are planned for cesarean delivery.

Brief summary: Diabetic parturients planned for cesarean delivery will be recruited for the study. They will receive a fixed glucose dose to mimize the effects of fasting preoperatively and their blood glucose levels will be monitored.

Detailed description: Informed voluntary parturients planned for cesarean delivery will be informed about the study. The parturients will get prepacked glucose drink containing 100 g and 50 g glucose, respectively. They will consume the 100 g of glucose the night before the planned operation and the 50 g on the morning of the planned cesarean delivery. Their blood glucose level will be monitored by percutaneous continuous blood glucose monitoring every 30 minutes for 2 hours following the glucose dose in the evening and for four hours in the morning of the operation.

The subjective well being of these parturients will be also qualitatively assessed.

Eligibility criteria: Inclusion Criteria:

* Volunteers to participate in the study
* Diabetes, either gestational or type II
* Planned for cesarean delivery

Exclusion Criteria:

* Type I diabetes

Primary outcomes:
measure: Increase of blood glucose following the oral glucose dose
timeFrame: 4 hours
Secondary outcomes:
measure: Maternal subjective well being after oral glucose dose during the preoperative fasting period
timeFrame: 4 hours
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: HUS/Women's hospital dept of obstetrics
Study officials:
References:
Clinical trial NCT02892578: Systematic Screening With Electrocardiogram for Unknown Atrial Fibrillation in 65 Years Old and Above People in Nursing Home
Official title: Systematic Screening With Electrocardiogram for Unknown Atrial Fibrillation in 65 Years Old and Above People in Nursing Home
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Atrial Fibrillation
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2016-09-08
Enrollment: 287
Sex: ALL
Minimum age (years): 65
Maximum age (years): 100
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Atrial fibrillation is the most common arrhythmia. Some studies shown that systematic screening with electrocardiogram could improve atrial fibrillation detection. No studies are available in nursing home. The goal of this study is to screen atrial fibrillation in patients who live in nursing home.

Detailed description: A prospective observational cross sectional multicenter study.

The goal of this study is to detect atrial fibrillation in nursing home people aged 65 years old and above, with systematic electrocardiogram. Participants agreement will be collected. Participants characteristics data will be collected in all nursing home. For all participants, one visit were realised with electrocardiogram, and symptoms survey. Data were anonymised on each center before analysed.

Eligibility criteria: Inclusion criteria :

* Being in nursing home since 1 month and above
* Aged \> 65 years old
* Subjects agree to participate at this project

Exclusion criteria :

* Antecedent of atrial fibrillation

Primary outcomes:
measure: presence of atrial fibrillation on electrocardiogram
timeFrame: up to 1 hour
Secondary outcomes:
measure: presence of irregular pulse
timeFrame: up to 1 hour
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Heart and vascular diseases service
Study officials:
References:
Clinical trial NCT05267678: Nutritional Deficiency and Recurrent Miscarriage
Official title: A Cohort Study Investigating Nutritional Deficiency Among Pregnant Women With History of Recurrent Miscarriage
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Recurrent Miscarriage
Lead sponsor: Westlake University
Sponsor class: OTHER
Collaborators: name: Peking Union Medical College Hospital
First posted: 2022-03-04
Enrollment: 499
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women with history of recurrent miscarriage

Brief summary: This prospective cohort study primarily aims to examine the association between blood niacin levels and recurrent miscarriage.

Detailed description: Recurrent miscarriage is affecting around 5% women at reproductive age. And the underlying causes remain undetermined in 50%-70% of cases. Although animal models and linkage analysis according to family studies have identified that niacin deficiency can lead to congenital malformations and recurrent miscarriage. Evidence based on population is lacking with regard to the effect of blood niacin levels on recurrent miscarriage. We intend to enroll 499 pregnant women confirmed by a positive blood human chorionic gonadotropin test and with history of unexplained recurrent miscarriage. By testing their blood niacin levels and following up to the end of first-trimester pregnancy, this study aims to examine the role of niacin levels in preventing miscarriages among women with history of recurrent miscarriage.

Eligibility criteria: Inclusion Criteria:

* 18-40years old, female
* Positive blood human chorionic gonadotropin test
* Naturally pregnant
* History of recurrent miscarriage (2 or more consecutive spontaneous miscarriage within 28 weeks of gestation)
* Willing to participate in this study with informed consent

Exclusion Criteria:

* Women whose confirmed cause of recurrent miscarriage has nothing to do with nutritional deficiencies, including chromosomal abnormalities, abnormal uterine anatomy, immune system diseases, blood diseases, etc.
* Women with Hepatitis B, syphilis, HIV/AIDS and other infectious diseases.
* Women with serious conditions, such as schizophrenia, tumors, heart failure

Primary outcomes:
measure: Number of participants with miscarriage
timeFrame: 6-13(+6) weeks of gestation
measure: Gestation week at miscarriage
timeFrame: 6-13(+6) weeks of gestation
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences
state: Beijing
Study officials:
affiliation: Westlake University
name: Hongjun Shi, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00718107: Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology
Official title: Satisfaction Survey for ALS Patients Comparing Rooms With and Without Assistive Technology
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Amyotrophic Lateral Sclerosis
Neurodegenerative Disease
Motor Neuron Disease
Keywords: Amyotrophic Lateral Sclerosis
Cerebrospinal Fluid
Neurodegenerative Disease
Motor Neuron Disease
Autonomic Nervous System
Neurodegenerative Diseases
Movement Disorders
Quality of Life
Lead sponsor: Drexel University
Sponsor class: OTHER
Collaborators: name: MDA/ALS Center of Hope
First posted: 2008-07-18
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: In-patients from the neurology floor of Hahnemann Hospital

Brief summary: The purpose of this study is :

1. To assess the ALS patient's satisfaction related to a hospital stay on the neurology floor of Hahnemann Hospital.
2. To compare the reported satisfaction of those individuals who stayed in a standard hospital room with those who stayed in Room 1455. Room 1455 is a room specifically set up with assistive technology related to environmental controls for individuals with disabilities.
3. To look at frequency of use of the various pieces of adaptive equipment.


Eligibility criteria: Inclusion Criteria:

* In-patients with probable or definite ALS, ages 18 - 90, staying on the neurology floor of Hahnemann Hospital

Exclusion Criteria:

* In-patients who do not meet the criteria of the diagnosis of ALS.

Primary outcomes:
measure: Patient Satisfaction
timeFrame: Period of Hospital Stay
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: MDA/ALS Center of Hope
state: Pennsylvania
Study officials:
References:
Clinical trial NCT01429207: Capturing Parkinson's Disease Medication Side Effects During Daily Activities
Official title: Phase I Study: Monitoring Levodopa-Induced Dyskinesia Using Accelerometer & Gyroscope-based Motion Detection System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson's Disease
Dyskinesia
Keywords: levodopa
tremor
bradykinesia
motion sensors
Lead sponsor: Great Lakes NeuroTechnologies Inc.
Sponsor class: INDUSTRY
Collaborators: name: University of Rochester
First posted: 2011-09-07
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Idiopathic PD demonstrating levodopa-induced dyskinesias

Brief summary: The purpose of the study is to test whether body-worn wireless motion sensors can measure dyskinesias (involuntary movements caused by medications) in individuals with Parkinson disease (PD) independent of voluntary activity being performed and other PD motor symptoms (e.g. tremor).


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of probable or definite idiopathic Parkinson Disease with motor fluctuations that include dyskinesias after taking their usual dose of levodopa/carbidopa

Exclusion Criteria:

* Antipsychotic medications (including quetiapine and clozapine)
* Coexisting neurologic disease such as stroke or dementia
* Lacking capacity for informed consent
* Residing in a nursing home
* comorbid non-neurologic illnesses that impacts the ability to perform the study tasks
* Implantable defibrillators

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester Medical Center
state: New York
Study officials:
References:
Clinical trial NCT00819507: VANOS Cream and Skin Barrier Function
Official title: Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Atopic Dermatitis
Keywords: Skin barrier
Atopic Dermatitis
Corticosteroid
Effects on skin severity and barrier function
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
Collaborators: name: Medicis Pharmaceutical Corporation
First posted: 2009-01-09
Enrollment: 25
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis. This cream is already approved for this indication, but the investigators will further examine its effects on the skin barrier. This cream is a novel formulation of fluocinonide designed to enhance compliance with a cream base, but have the skin barrier repair properties of an ointment.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of AD according to Hanifin-Rajka criteria (see Appendix B)
* Age 12 years or older
* Must have an Investigator's Global Assessment (IGA) Score of Moderate, Severe, or Very Severe (See Appendix C)
* Must have failed to achieve adequate disease despite adequate topical or systemic therapy
* Must be a candidate, according to the principal investigator and standard of care, for a super-potent topical steroid course. Subjects that are candidates for super-potent topical steroids are defined as subjects whose disease is not adequately controlled with medium-potency topical steroids or systemic therapy, including phototherapy.

Exclusion Criteria:

* Active skin infection
* Hypersensitivity to any ingredients in Vanos cream
* Previous use of super-potent topical steroids within 2 weeks of starting study (Class I steroid).

Primary outcomes:
measure: Change in Eczema Severity and Area Index
timeFrame: 2 Weeks
Secondary outcomes:
measure: Change in Transepidermal Water Loss
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health & Science University Department of Dermatology
state: Oregon
Study officials:
References: